Novakand Pharma AB (FRA:3EE0) Total Equity: €1.38 Mil (As of Dec. 2025)


What is Novakand Pharma AB Total Equity?

Novakand Pharma AB FRA:3EE0 Total Equity is €1.38 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Novakand Pharma AB's total equity for the quarter that ended in Dec. 2025 was €1.38 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Novakand Pharma AB Total Equity Historical Data

* Premium members only.

The historical data trend for Novakand Pharma AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novakand Pharma AB Total Equity Chart

Novakand Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.93 9.73 4.26 5.42 1.38

Novakand Pharma AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.42 4.51 3.92 1.82 1.38

Novakand Pharma AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Novakand Pharma AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1.538-0.153
=1.39

Novakand Pharma AB's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1.538-0.153
=1.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €1.38 Mil mean?
Novakand Pharma AB (FRA:3EE0) has a Total Equity of €1.38 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Novakand Pharma AB and its competitors.
Is Novakand Pharma AB's Total Equity too high?
Novakand Pharma AB's current Total Equity is €1.38 Mil.
How does Novakand Pharma AB's Total Equity compare to VRTX and REGN?
Novakand Pharma AB's Total Equity of €1.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Novakand Pharma AB and its competitors. Novakand Pharma AB's current Total Equity is €1.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novakand Pharma AB stock overvalued right now?
Novakand Pharma AB (FRA:3EE0) has a current Total Equity of €1.38 Mil. The current Total Equity is €1.38 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Novakand Pharma AB (FRA:3EE0), the current Total Equity is €1.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novakand Pharma AB Business Description

Address Nanna Svarts vag 4, Solna, SWE, 171 65
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.